HT1080 Fibrosarcoma With Acquired Trabectedin Resistance: Increased Malignancy But Sustained Sensitivity to Methionine Restriction
TR-HT1080 cells acquired high malignancy by <i>in vitro</i> selection for trabectedin resistance. However, methionine restriction overcame trabectedin resistance <i>in vivo</i>, strongly inhibiting tumor growth, which should be further investigated in the clinic.
Authors
- Michael Bouvet (ORCID: https://orcid.org/0000-0002-0086-2159)
- Shinji Miwa (ORCID: https://orcid.org/0000-0002-5962-8287)
- Byung Mo Kang (ORCID: https://orcid.org/0000-0003-0900-094X)
- Katsuhiro Hayashi (ORCID: https://orcid.org/0000-0001-8665-2154)
- Norio Yamamoto (ORCID: https://orcid.org/0000-0002-7250-625X)
- Robert M. Hoffman (ORCID: https://orcid.org/0000-0002-0049-0041)
- Takashi Higuchi (ORCID: https://orcid.org/0000-0003-2896-4939)
- Hiroyuki Tsuchiya (ORCID: https://orcid.org/0000-0003-0730-7921)
- KOHEI MIZUTA
- Satoru Demura
- Kentaro Igarashi (ORCID: https://orcid.org/0000-0003-2278-1736)
- Sei Morinaga (ORCID: https://orcid.org/0000-0003-2961-9432)
- Hiroaki Kimura (ORCID: https://orcid.org/0000-0003-2145-8726)
- Qinghong Han
Institutions
- Kanazawa University (JP)
- University of California San Diego (US)
- AntiCancer (United States) (US)
Publication Details
- Journal
- In Vivo
- Published
- 2025-02-26
- DOI
- https://doi.org/10.21873/invivo.13872
- Citations
- 2
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04